Onclive Team

A modified intraperitoneal (IP) regimen for advanced ovarian cancer demonstrated feasibility, tolerability, and evidence of effectiveness, results of a small pilot study suggest.

Many contemporary issues in the US healthcare system affect clinicians in all areas of medicine. Some issues are even more specific to the field of gynecologic oncology.

Prior approval improves chances of being reimbursed, increases practice costs, and can delay treatment.

Hans-Peter Gerber has been building a program to develop novel biotherapeutics for oncology, including antibody-drug conjugates, at the Pfizer Oncology Research Unit in Pearl River, New York.

Recent clinical and economic studies have suggested that ovarian cancer regimens containing bevacizumab could fall within the boundaries of cost-effectiveness, at least for some patients.

Three-fourths of patients with advanced hepatocellular carcinoma associated with hepatitis C infection achieved disease control with antibody therapy directed at a T-cell antigen.

The cancer proliferation marker Ki-67 decreased significantly in men who took high-dose vitamin D in the weeks leading up to radical prostatectomy for localized prostate cancer.

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Breast cancer survival improved significantly in patients who increased consumption of cruciferous vegetables following diagnosis, a study of Chinese women showed.

A compilation of photos from the 2012 combined conferences of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO).

Four studies reflected the growing interest in-and the volume of evidence for-using the diabetes drug metformin as a potential cancer therapy.

Control of chemotherapy-induced nausea and vomiting (CINV) has come a long way in the past 30 years. Thirty years ago, about 10% of patients had complete control of emesis; in the 1990s about 50% had complete control. Today about 85% of patients treated with highly emetogenic chemotherapy have complete control of emesis.

Treatment of febrile neutropenia (FN) has dramatically improved over the past 3 decades, but there is room for improvement, according to Jean Klastersky, MD, Institut Jules Bordet, Brussels, Belgium.

A chronic shortage of the most commonly used taxane for ovarian cancer would add almost $9 million a month to the cost of care if half of newly diagnosed cases were affected.

Most recurrent endometrial tumors have the same PI3K/Akt mutation profile as found in the primary tumor.

Unexpected target mutations likely doomed a proven therapeutic approach to lung cancer in a test against glioblastoma.

Cancer drugs once deemed too toxic for humans have earned a second chance at therapeutic utility, in part because of a reversal in the usual progression of medical research.

A pilot program in Michigan strives to keep oncologists in the community by basing reimbursement on care management.

An interview with ASCO President Michael P. Link, MD, discussing the impact of oncology drug shortages.

Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

To learn more about how photopheresis can help patients fight the symptoms of CTCL, OncologyLive spoke with Dennis Parenti, MD, vice president of Clinical Affairs for Therakos.

Patients who live far from medical facilities benefit from having "virtual" conversations with their doctors and are comfortable with that arrangement.

Photos taken from the AACE 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.

Oliver Sartor, MD, and Leonard G. Gomella, MD, discuss multiple topics involved with prostate-specific antigen (PSA) screening, including PSA velocity, guidelines, and cutoff age.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Five nurses discuss the value of the Oncology Nursing Society (ONS) Annual Congress, which is the largest meeting held specifically for oncology nurses.

Discussion with Andrew D. Zelenetz, MD, PhD, on a number of new therapies and interesting challenges regarding the treatment of patients with both Hodgkin and non- Hodgkin lymphoma.

The Oncology Nursing Society (ONS) 37th Annual Congress video highlights, from OncLive TV.